Show simple item record

dc.contributor.authorKarabulut, B.
dc.contributor.authorErten, C.
dc.contributor.authorGül, M. K.
dc.contributor.authorCengiz, E.
dc.contributor.authorKaraca, B.
dc.contributor.authorKüçükzeybek, Y.
dc.contributor.authorGörümlü, G.
dc.contributor.authorAtmaca, H.
dc.contributor.authorUzunoğlu, S.
dc.contributor.authorŞanlı, U. A.
dc.contributor.authorBaran, Yusuf
dc.contributor.authorUslu, R.
dc.date.accessioned2017-01-26T12:04:46Z
dc.date.available2017-01-26T12:04:46Z
dc.date.issued2009-02
dc.identifier.citationKarabulut, B., Erten, C., Gül, M. K., Cengiz, E., Karaca, B., Küçükzeybek, Y., Görümlü, G., Atmaca, H., Uzunoğlu, S., Şanlı, U. A., Baran, Y., and Uslu, R. (2009). Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biology International, 33(2), 239-246. doi:10.1016/j.cellbi.2008.11.011en_US
dc.identifier.issn1065-6995
dc.identifier.urihttp://doi.org/10.1016/j.cellbi.2008.11.011
dc.identifier.urihttp://hdl.handle.net/11147/2865
dc.description.abstractDocetaxel, a semi-synthetic taxane analogue, is used effectively in the treatment of metastatic prostate cancer. Zoledronic acid, the most potent member of bisphosphonates, has shown pleiotropic anti-tumoral effects on prostate cancer cells. We have explored the possible additive/synergistic effects and the apoptotic pathways induced by combination treatment of docetaxel and zoledronic acid in hormone and drug refractory, PC-3 and DU-145 prostate cancer cells. Combination of docetaxel and zoledronic acid synergistically inhibits cell growth in PC-3 and DU-145 cells. Moreover, this effect was due to downregulation of antiapoptotic protein Bcl-2 in PC-3 and DU-145 cells. In conclusion, docetaxel/zoledronic acid combination is potentially a novel and effective approach for the treatment of prostate cancer.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1016/j.cellbi.2008.11.011en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectZoledronic aciden_US
dc.subjectProstate canceren_US
dc.subjectDocetaxelen_US
dc.subjectBcl-2en_US
dc.subjectDU-145en_US
dc.subjectPC-3en_US
dc.titleDocetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cellsen_US
dc.typearticleen_US
dc.contributor.authorIDTR119193en_US
dc.contributor.iztechauthorBaran, Yusuf
dc.relation.journalCell Biology Internationalen_US
dc.contributor.departmentİYTE, Fen Fakültesi, Moleküler Biyoloji ve Genetik Bölümüen_US
dc.identifier.volume33en_US
dc.identifier.issue2en_US
dc.identifier.startpage239en_US
dc.identifier.endpage246en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record